Moreover, treatment of mice bearing KRAS WT tumors with the ferroptosis-selective inhibitor Liproxstatin-1 accelerated tumor onset to similar levels as FSP1 overexpression suggesting ferroptosis to be indeed responsible for suppression of tumor initiation capacity of WT cells in vivo. This evidence concerns the gene AIFM2 and neoplasm.